Efficacy and safety of endocrine therapy for breast-cancer prevention in high-risk premenopausal or postmenopausal women: a Bayesian network meta-analysis of nine randomized controlled trials
Conclusions and Relevance:
To sum up, ET decreased the risks of TBC, IBC, ER + BC, and ductal carcinoma in situ, while increasing the risks of pulmonary embolism, total venous thrombosis, and EC in high-risk pre- or postmenopausal women. Meanwhile, anastrozole, exemestane, and tamoxifen possibly exerted potential protective effects on TBC, IBC and ER + BC. Typically, raloxifene might be effective on IBC, while tamoxifen might increase the risk of EC. Therefore, clinicians should fully weigh the benefits and risks of ET to develop a rational individualized treatment.
Source: Menopause - Category: OBGYN Tags: Review Article Source Type: research
More News: Arimidex | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Databases & Libraries | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Endocrine Therapy | Endometrial Cancer | Evista | Men | Menopause | OBGYN | Pulmonary Thromboembolism | Study | Tamoxifen | Thrombosis | Women